Ophthalmic Consultants of Boston
Quick facts
Marketed products
- Intravitreal Aflibercept Injection · Ophthalmology
Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye. - Moxifloxacin ophthalmic solution 0.5% · Ophthalmology / Infectious Disease
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Ophthalmic Consultants of Boston portfolio CI brief
- Ophthalmic Consultants of Boston pipeline updates RSS
Frequently asked questions about Ophthalmic Consultants of Boston
What are Ophthalmic Consultants of Boston's marketed drugs?
Top marketed products include Intravitreal Aflibercept Injection, Moxifloxacin ophthalmic solution 0.5%.
Related
- Intravitreal Aflibercept Injection · Ophthalmology
- Moxifloxacin ophthalmic solution 0.5% · Ophthalmology / Infectious Disease
- Sector hub: All tracked pharma companies